Pipeline
Immuno-Oncology
HomePipelineImmuno-Oncology
Publications
Park E et al. The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation. PEGS Boston 2019
Cancer Immuno-Oncology
Conditional 4-1BB Agonist: TAA (Tumor Associated Antigen)-Dependent 4-1BB Agonistic Effect
ABL’s Grabody™ T Platform is Engineered to Activate T cells in the Presence of TAA within the Tumor Microenvironment
ABL’s Grabody™ T BsAb is engineered to activate T-cells only at the Tumor Microenvironment (Strong Safety Profile)
Anti-Tumor Effect with ABL’s Grabody™ T BsAb
No Liver Toxicity with ABL’s Grabody™ T BsAb
ABL’s Grabody™ I Platform : Immunomodulatory Effects of PD-L1-based Dual Immune Checkpoint Blockade
Mechanism of Action of Grabody™ I
ABL’s Grabody™ I
ABL501 is a Dual Immune Checkpoint Blockade (PD-L1 & LAG-3)
Superior T Cell Activation than Combination by ABL’s Grabody™ I BsAb
Recent Immuno-Oncology & Bispecific Antibody Deals : "Early Stage & Bigger Deals"
The Latest Licensing Deals of Immuno-Oncology with Bispecific Technology
